MUPS timeline: A historical scetch of Multiple Unit Pellet System

Historical Timeline of Multiparticulate Unit Pellet Systems (MUPS) in Pharmaceutical Development

Multiparticulate Unit Pellet Systems (MUPS) represent one of the most significant advances in oral modified-release drug delivery. Unlike conventional monolithic tablets, MUPS consist of hundreds to thousands of coated pellets compressed into a tablet or filled into capsules, allowing controlled drug release while maintaining the advantages of multiparticulate dosage forms. Bringing MUPS in a timeline seems to be an exciting and impressive adventure.

The development of MUPS spans more than 70 years, evolving alongside advances in pelletization technology, polymer science, and pharmaceutical manufacturing.

1950s
Coated sustained-release pellets
Early sustained-release pellets. First attempts to produce coated granules and beads for prolonged drug release.
Multiparticulate capsule products
Commercial multiparticulates. Introduction of coated bead-filled capsules for controlled release.

1960s
1970s
Fluid-bed coating becomes widespread
Modern pelletization technologies. Development of extrusion–spheronization and fluid-bed coating.
Practical MUPS technology established
Birth of MUPS concept. Compression of coated pellets into tablets becomes technically feasible.

1980s
1990s
Commercial launch of omeprazole MUPS
Commercial success. Launch of omeprazole MUPS tablets establishes the platform.
Expansion to multiple therapeutic classes
Platform expansion. Wider adoption for acid-labile and modified-release drugs.

2000s
2010s
QbD, PAT, and risk-based development
Quality-by-Design (QbD) era. Improved manufacturing robustness and regulatory acceptance.
Continuous manufacturing and personalized MUPS research
Advanced MUPS. Continuous manufacturing, PAT, 3D printing research, personalized medicines.

2020s

Until the 1950s: Foundations of Multiparticulate Drug Delivery

The earliest sustained-release oral formulations relied on:

coated sugar spheres
wax-coated granules
resin complexes
coated crystals

These systems demonstrated that dividing the dose into many small units reduced variability in gastrointestinal transit compared with single tablets.

Major developments included:

sugar-based starter cores
solvent-based coating technologies
cellulose derivatives as release modifiers

These products were typically filled into hard gelatin capsules rather than compressed into tablets.

1960s: Emergence of Multiparticulate Capsules

During the 1960s, pharmaceutical scientists recognized several advantages of multiparticulates:

reduced dose dumping
more uniform GI distribution
lower risk of local irritation
improved reproducibility of drug absorption

Commercial sustained-release capsule technologies became increasingly common, using:

sugar spheres
nonpareil seeds
coated beads
layered pellets

Coating polymers such as ethylcellulose and cellulose acetate became widely adopted.

1970s: Revolution in Pellet Manufacturing

This decade produced the manufacturing technologies that made modern MUPS possible.

Extrusion–Spheronization

Developed into a reliable industrial process, extrusion–spheronization enabled production of highly spherical pellets with:

narrow size distribution
excellent mechanical strength
high drug loading
reproducible coating behavior

Microcrystalline cellulose became the standard pelletization excipient.

Fluid-Bed Coating

Fluid-bed coaters allowed:

uniform polymer coatings
enteric coatings
sustained-release membranes
functional multilayer coatings

This was a major enabling technology for multiparticulate systems.

1980s: Birth of MUPS Technology

Researchers demonstrated that pellets could survive tableting if:

pellet cores were sufficiently strong
coatings were sufficiently elastic
compression forces were carefully controlled
cushioning excipients protected pellet integrity

This represented the birth of the modern MUPS concept.

Key scientific advances included:

acrylic polymer coatings
flexible enteric coatings
optimized pellet size (typically 0.1–1.5 mm)
low-friction tableting formulations

1990s: Commercial Breakthrough

The major milestone in MUPS timeline was the introduction of Losec MUPS (known as Prilosec in some markets), developed by AstraZeneca.

The formulation consisted of:

enteric-coated omeprazole pellets
compressed into a rapidly disintegrating tablet
each pellet maintaining its own release characteristics

This solved several practical problems:

easier swallowing than capsules
reduced risk of chewing damage
flexible dosing
preserved enteric protection

The commercial success of Losec MUPS demonstrated that MUPS could be manufactured at industrial scale while preserving pellet functionality.

2000s: Platform Expansion

Following the success of omeprazole MUPS, the technology expanded to many therapeutic areas.

Applications included:

proton pump inhibitors
delayed-release formulations
sustained-release products
combination products

Common polymers included:

methacrylate copolymers
ethylcellulose
cellulose acetate
hypromellose phthalate
polyvinyl acetate dispersions

Manufacturers increasingly optimized:

pellet porosity
coating thickness
tablet disintegration
pellet compressibility

2010s: Quality-by-Design and Process Understanding

The pharmaceutical industry adopted Quality by Design (QbD) principles for MUPS development.

Research shifted from empirical formulation toward mechanistic understanding.

Critical Quality Attributes (CQAs) included:

pellet size distribution
sphericity
friability
coating thickness
coating uniformity
tablet hardness
pellet integrity after compression
dissolution profile

Critical Process Parameters (CPPs) included:

extrusion moisture
spheronization speed
coating atomization
inlet air temperature
compression force

Process Analytical Technology (PAT) and statistical design of experiments became widely used to optimize robustness.

2020s: Milestone in MUPS Timeline – Advanced MUPS

Current research focuses on increasingly sophisticated systems.

Continuous Manufacturing

Instead of batch processing:

continuous extrusion
continuous coating
real-time monitoring
automated control

are being explored.

Personalized Medicine

Research investigates:

variable pellet mixtures
individualized dosing
pediatric formulations
geriatric formulations

Novel Pellet Technologies

Emerging approaches include:

hot-melt extrusion pellets
lipid-based pellets
osmotic pellets
layered pellets with multiple APIs
amorphous solid dispersion pellets

Digital Manufacturing

Current research explores:

3D-printed MUPS tablets
AI-assisted process optimization
digital twins
real-time release testing

Although most remain at the research or early development stage, they illustrate the direction of future innovation.

Overall Evolution

The evolution of MUPS in a timeline can be viewed in four phases:

Concept (1940s–1960s): Demonstration that multiparticulates improve drug release consistency and gastrointestinal distribution.
Technology Development (1970s–1980s): Advances in pelletization, coating, and compression science made MUPS technically feasible.
Commercialization (1990s–2000s): Successful products—most notably omeprazole MUPS—validated the platform and drove broader adoption.
Optimization (2010s–present): Modern MUPS development emphasizes robust process understanding, regulatory science, advanced manufacturing, and personalized oral drug delivery.

Today, MUPS are considered a mature yet actively evolving platform for oral modified-release formulations, especially where reliable gastrointestinal distribution, protection of acid-sensitive drugs, or flexible release profiles are required.